P351: PROTEASOME INHIBITORS INDUCE DNA DAMAGE AND MITOTIC CATASTROPHE IN ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) VIA AUTOPHAGY-MEDIATED DEGRADATION OF WEE1

Documenti analoghi

• Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?
  di: Giuseppe Fanciulli, et al.
  Pubblicazione: (2023-04-01)
• Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system
  di: Shuyue Li, et al.
  Pubblicazione: (2026-01-01)
• Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
  di: Marta Pelon, et al.
  Pubblicazione: (2024-03-01)
• Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
  di: Denise Niewerth, et al.
  Pubblicazione: (2016-09-01)
• Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
  di: Mariah L. Farrell, et al.
  Pubblicazione: (2018-05-01)